Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Cancer Discov. 2020 Jun 30;10(10):1500–1513. doi: 10.1158/2159-8290.CD-19-1469

Figure 2. Differential apoptotic thresholds in murine and human MLL-AF9 leukemias arising from distinct cells of origin.

Figure 2.

LSK- and GMP-derived MLL-AF9 leukemias were treated with DMSO or 1 μM IMG-7289. (A) Viable DAPI− cells were enumerated after 48 hours of treatment. (B) Annexin V and DAPI staining was assessed by flow cytometry. p<0.03, using Student’s t-test comparing percent Annexin V-positive cells between GMP- and LSK-derived. Data shown are representative of 3 independent experiments. (C) TMRE staining was measured by flow cytometry as a readout of mitochondrial membrane potential after 48 hours of treatment. Statistical analyses summarized in (D). Data shown are representative of 3 independent experiments. (D) Summary scatter plots depicting the percentage of cells within the ψlow gate defined by TMRE flow cytometry in (C). BH3 profiling of (E) murine LSK- and GMP-derived MLL-AF9 leukemia cells or (F) human cord blood HSC- and GMP-derived leukemias exposed to DMSO control or pro-apoptotic peptides.